The Motley Fool on MSN1d
Got $5,000? Viking Therapeutics Stock Just Got a Big New Green Flag
The company's latest presentation supports the idea that its lead program will make billions.
Viking Therapeutics’ weight-loss pill shows ‘great outcome’ in trial
Viking Therapeutics Inc. cheered analysts Monday after the biotech posted data on its oral weight-loss drug showing ...
Viking Therapeutics stock falling amid results for new GLP-1 pill
Viking Therapeutics (VKTX) shares are taking a dive in Monday's session despite on rising manufacturing concerns and ...
MM&M3d
Viking Therapeutics’ GLP-1 pill candidate shows promise in latest study
Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage ...
Promising Pipeline and Financial Stability Drive Buy Rating for Xilio Therapeutics
Morgan Stanley analyst Michael Ulz has maintained their bullish stance on XLO stock, giving a Buy rating yesterday. Michael Ulz has given his ...
Viking Therapeutics: Q3 Earnings Report Loads A Barrage Of Catalysts
Viking Therapeutics shows significant clinical progress in obesity and NASH. Learn more about VKTX stock and its potential ...
The Motley Fool on MSN3d
Is Viking Therepautics a Buy Now?
Viking Therapeutics reported clinical trial data on Sunday, which excited some investors. Despite signs that Viking's ...
Promising Growth Potential for Keros Therapeutics Driven by Robust Clinical Pipeline and Upcoming Data Releases
Leerink Partners analyst Thomas Smith has reiterated their bullish stance on KROS stock, giving a Buy rating yesterday. Thomas Smith’s ...